|
Elevation Oncology, Inc. (ELEV): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Elevation Oncology, Inc. (ELEV) Bundle
In the rapidly evolving landscape of precision oncology, Elevation Oncology, Inc. (ELEV) stands at the forefront of molecular targeted cancer therapies, transforming how we approach rare and challenging malignancies. With a laser-focused strategy targeting specific molecular alterations, this innovative biotech company is pioneering groundbreaking treatments that promise to redefine personalized cancer care. Dive into our comprehensive analysis of ELEV's marketing mix to uncover how this cutting-edge organization is strategically positioning itself to revolutionize oncological treatment in 2024 and beyond.
Elevation Oncology, Inc. (ELEV) - Marketing Mix: Product
Precision Oncology Therapeutics Pipeline
Elevation Oncology focuses on developing targeted molecular therapies for cancer treatment, with a specific emphasis on rare and challenging cancer types.
| Product | Target | Cancer Type | Development Stage |
|---|---|---|---|
| ELEV-080 | NaPi2b | Lung and Ovarian Cancer | Phase 1/2 Clinical Trial |
| ELEV-120 | TRK Fusion | Solid Tumors | Preclinical Stage |
Key Product Characteristics
- Antibody-drug conjugate (ADC) technology platform
- Molecular targeting approach for personalized cancer treatment
- Focus on rare and difficult-to-treat cancer subtypes
Lead Product: ELEV-080
Molecular Targeting Details:
- Targets NaPi2b protein overexpressed in certain cancers
- Designed for precision delivery of therapeutic payload
- Potential application in lung and ovarian cancer treatment
Clinical Development Strategy
| Development Metric | Current Status |
|---|---|
| Active Clinical Trials | 2 ongoing trials |
| Total Research Investment | $42.3 million (2023 fiscal year) |
| Patent Portfolio | 7 granted patents |
Product Innovation Approach
Elevation Oncology utilizes advanced molecular targeting techniques to develop therapeutics with potential for personalized cancer treatment strategies.
Elevation Oncology, Inc. (ELEV) - Marketing Mix: Place
United States Biopharmaceutical Market Presence
Elevation Oncology operates exclusively within the United States oncology treatment market, focusing on targeted therapeutic interventions.
| Geographic Concentration | Details |
|---|---|
| Primary Market | United States |
| Research Headquarters | Boston, Massachusetts |
| Clinical Trial Regions | Multiple U.S. metropolitan areas |
Research and Development Location
Centered in the Boston, Massachusetts biotech ecosystem, leveraging proximity to leading research institutions and medical centers.
Distribution Channels
- Specialized oncology treatment centers
- Academic medical institutions
- Digital research platforms
- Direct clinical trial engagement sites
Clinical Trial Geographic Reach
| Trial Type | Number of Sites | Geographic Coverage |
|---|---|---|
| Ongoing Oncology Trials | 12-15 active sites | Nationwide U.S. coverage |
Digital Platform Engagement
Digital research platforms utilized for patient recruitment, clinical data management, and remote monitoring of clinical trials.
Institutional Partnerships
- Top-tier cancer research centers
- National comprehensive cancer networks
- Specialized oncology research hospitals
Elevation Oncology, Inc. (ELEV) - Marketing Mix: Promotion
Presenting Research at Major Oncology Conferences
Elevation Oncology has actively participated in key oncology conferences to showcase its clinical research and molecular targeted therapies.
| Conference | Year | Presentations |
|---|---|---|
| American Society of Clinical Oncology (ASCO) | 2023 | 3 scientific abstracts |
| European Society for Medical Oncology (ESMO) | 2023 | 2 research presentations |
Investor Relations Communications
The company utilizes strategic investor communications to highlight clinical development progress.
- Quarterly earnings calls
- Investor presentations
- SEC filing updates
Healthcare Professional Engagement
Targeted medical communications focus on educating specialists about molecular targeted therapies.
| Communication Channel | Frequency |
|---|---|
| Medical journal advertisements | Quarterly |
| Oncology specialist webinars | Bi-annually |
Press Release and Corporate Communications
Transparent updates are provided through various communication channels.
- Press releases in 2023: 12
- Corporate website updates
- Social media announcements
Educational Materials Development
Comprehensive educational resources about molecular targeted cancer therapies are created.
| Material Type | Target Audience |
|---|---|
| Scientific white papers | Researchers and clinicians |
| Patient information brochures | Potential treatment candidates |
Elevation Oncology, Inc. (ELEV) - Marketing Mix: Price
Company Financial Overview
As of Q4 2023, Elevation Oncology reported:
| Financial Metric | Value |
|---|---|
| Cash and Cash Equivalents | $72.4 million |
| Net Loss | $35.2 million |
| Research and Development Expenses | $24.6 million |
Stock Performance
ELEV stock trading details:
- Current Stock Price: $1.87 (as of February 2024)
- 52-week Range: $1.20 - $4.35
- Market Capitalization: Approximately $53 million
Pricing Strategy Considerations
Precision oncology treatment market pricing benchmarks:
| Treatment Category | Estimated Annual Cost |
|---|---|
| Targeted Therapies | $100,000 - $400,000 |
| Immunotherapies | $150,000 - $500,000 |
Investment and Funding
Funding sources breakdown:
- Venture Capital Investments: $45.6 million
- Public Market Offerings: $37.2 million
- Strategic Partnerships: $12.5 million
Clinical Development Milestones Pricing Impact
Key pricing influencers:
- Phase 2 clinical trial progression
- Therapeutic efficacy data
- Potential FDA approval trajectory
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.